{
	"l1liuzmsText": "<span style=\"color: rgba(76, 126, 133, 0);\">High anxiety</span><span class=\"_ _1a\"> </span>T<span class=\"_ _1\"></span>rauma",
	"l1liuzmtText": "In patients with sever<span class=\"_ _1\"></span>e MDD and severe comorbid<br>GAD<span class=\"_ _9\"></span>,<span class=\"_ _1\"></span> Brintellix<span class=\"fse wsd v6\">®</span><span class=\"v0\"> 10-20 mg significantly r<span class=\"_ _1\"></span>educed symptoms <br>of<span class=\"_ _7\"></span> depression,<span class=\"_ _1\"></span> including anxiety<span class=\"fse v6\">†1</span></span>",
	"l1liuzn0Text": "Study Design",
	"l1liuzn1Text": "Zoom",
	"l1liuzn8Text": "Comorbid GAD<span class=\"_ _1d\"> </span><span class=\"ff6 fc0\">Real-W<span class=\"_ _1\"></span>orld Data (REVIDA)<span class=\"_ _1e\"></span>HAM-A &gt; 20</span>",
	"l1liuzn9Text": "High anxiety",
	"l1liuznaText": "Emotional",
	"l1liuznbText": "Blunting",
	"Brintellix_NewAss_6b53814b3": "<div style=\"color:#646162; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px; margin-bottom:20px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> 94% of patients increased the dose of Brintellix<sup style=\"font-size:50%;\">®</sup> to 20 mg after 1 week of treatment and 87%<br>maintained this higher dose throughout the study period<sup style=\"font-size:50%;\">1</sup></div>\n<div style=\"color:#646162; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> No clinically relevant difference was observed in AEs in patients who increased to 20 mg<br>compared to those who stayed on 10 mg<sup style=\"font-size:50%;\">1</sup></div>",
	"Brintellix_NewAss_60953bfbd": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">\n<sup style=\"font-size:50%;\">†</sup>Interventional, open-label effectiveness study of flexible doses of Brintellix<sup style=\"font-size:50%;\">®</sup> (10-20 mg/day) on depressive and anxiety symptoms in<br>patients with MDD and comorbid generalised anxiety disorder (GAD). At baseline, patients had severe MDD (MADRS total score = 29.5<br>points) and severe GAD (HAM-A total score = 28.6 points). 77% had inadequate responses to previous antidepressant treatments.<sup style=\"font-size:50%;\">1</sup><br>\nVortioxetine is indicated for the treatment of MDD.<sup style=\"font-size:50%;\">2</sup><br>\n<sup style=\"font-size:50%;\">‡</sup>Change in depressive symptoms was measured by assessing the change from baseline in MADRS total score at week 8; baseline: 29.5.<br>\n<sup style=\"font-size:50%;\">§</sup>Change in anxiety symptoms was measured by assessing the change from baseline in HAM-A total score at week 8; at baseline: 28.6.<br>\n***p&lt;0.0001 vs baseline.<br><br>\nAEs, adverse events; FAS, full analysis set; GAD, generalised anxiety disorder; HAM-A, Hamilton anxiety rating scale; MADRS, Montgomery–<br>Åsberg depression rating scale; MDD, major depressive disorder; MDE, major depressive episode; MMRM, mixed-model repeated-measures analysis.\n</div>",
	"Brintellix_NewAss_69c0dfd5f": "<span style=\"color: rgb(77, 127, 134); font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_NewAss_6bb8c3c89": "<font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font><div style=\"margin:5px 0 0;\"><font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>2.</b></font></div>",
	"Brintellix_NewAss_6efb882fe": "<div style=\"margin-bottom:5px;\"><font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Christensen MC et al. Poster presented at ECNP. P.0073.2021.</font></div>\n<div style=\"margin-bottom:5px;\"><font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Lundbeck. Brintellix<sup style=\"font-size:50%;\">®</sup> Summary of Product Characteristics. July 2021.</font></div>",
	"Brintellix_NewAss_66485fa47": "Text",
	"Brintellix_NewAss_6b53b0c11": "Text",
	"Brintellix_NewAss_65ef5eb08": "Text",
	"Brintellix_NewAss_69eaba5b0": "Text"
}
